Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
BRAF-targeted paired box gene-8 (PAX8), a thyroid-specific transcription factor, generally dysregulated in BRAF-mutated thyroid cancer.
|
30760304 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients with RAIR, BRAF mutant thyroid cancer.
|
30256977 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Although most of the US Food and Drug Administration (FDA)-approved drugs are antiangiogenic multikinase inhibitors-vandetanib, cabozantinib, sorafenib, lenvatinib-there are two FDA indications that are mutation specific-dabrafenib/trametinib for BRAF-mutated anaplastic thyroid cancer and larotrectinib for NTRK-fusion thyroid cancer.
|
31322645 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BRAFi inhibited ERK signaling in BRAF<sup>V600E</sup> mutants, but not BRAF wild-type thyroid cancer cell lines.
|
31097454 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
Effects of curcumin and its adjuvant on TPC1 thyroid cell line.
|
30935902 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We aimed to investigate the diagnostic value of the BRAF mutation in cytologically indeterminate thyroid nodules after the reclassification of a variant thyroid carcinoma.
|
30863114 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
BRAF V600E mutations are common in papillary thyroid carcinoma (PTC) and some de-differentiated thyroid cancers.
|
31529211 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we provide an overview on the current knowledge concerning the mechanisms leading to resistance to BRAF inhibitors in human thyroid carcinomas and discuss the potential therapeutic strategies, including combinations of BRAF inhibitors with other targeted agents, which might be employed to overcome drug resistance and potentiate the activity of single agent BRAF inhibitors.
|
31540406 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Hence, recent research efforts have been performed trying to explore several inhibitors of the V600E mutation-containing BRAF kinase as potential therapeutic options in thyroid cancer refractory to standard interventions.
|
30481266 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, glycolysis-related enzymes, such as LDHA and PKM2, were upregulated in BRAF V600E mutant thyroid cancer specimens, thereby promoting glycolysis.
|
30768848 |
2019 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, the results of the current study suggest that BRAF<sup>V600E</sup>-induced KRT19 expression may promote thyroid cancer metastasis via EMT.
|
31289571 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
CTD_human |
A Toxicogenomic Approach Reveals a Novel Gene Regulatory Network Active in In Vitro and In Vivo Models of Thyroid Carcinogenesis.
|
30621213 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Lysyl Oxidase Is a Key Player in BRAF/MAPK Pathway-Driven Thyroid Cancer Aggressiveness.
|
30398411 |
2019 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combination strategies involving immune checkpoint inhibitors (ICIs) with tyrosine kinase (TK) or serine/threonine protein kinase B-raf (BRAF) inhibitors are showing considerable promise in the treatment of advanced thyroid cancer.
|
31412566 |
2019 |
Thyroid carcinoma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
The mixed expression of BRAF under varying levels of differentiation may explain, in part, the contradictory studies regarding the impact of BRAF mutations on patient prognosis and also indicates a complex genomic signature for dedifferentiated thyroid cancer.
|
31229486 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines.
|
30531837 |
2019 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
|
30036146 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate detection of hallmark BRAF V600E mutations by NGS within infarcted tissue of thyroid carcinomas after FNA.
|
29868707 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
However, the response to vemurafenib is limited in BRAF-mutant thyroid cancer.
|
29737325 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid cancer (PTC) accounts for more than 97 % of thyroid cancer and 80% or more PTC cases harbor the BRAF mutation in Korea.
|
28258306 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma.
|
29579361 |
2018 |
Thyroid carcinoma
|
0.600 |
Biomarker
|
disease |
BEFREE |
The specific mechanisms of BRAF<sup>V600E</sup> and the unknown pathway associated with Mps1 exhibit potential for further study, and provide a theoretical basis for the molecular treatment of thyroid carcinoma.
|
29805692 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A selective inhibitor of BRAF V600E has been proposed as a novel treatment for patients with thyroid cancer exhibiting BRAF V600E mutations.
|
29616135 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Specimens of pituitary adenomas and thyroid cancer were collected for BRAF mutation assessments.
|
29593792 |
2018 |
Thyroid carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutations and their correlation with BRAF and RAS mutations in a consecutive cohort of 145 thyroid cancer cases.
|
29435002 |
2018 |